Topical Antifungals Global Market Report 2025

The topical antifungals market size has grown strongly in recent years. It will grow from $5.64 billion in 2024 to $6.02 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. Growth during the historical period was driven by an increase in hospital-acquired infections, growing preference for topical treatments, rising incidence of aspergillus-related infections, higher demand for antifungal therapies, and a surge in diabetes prevalence.

The topical antifungals market size is expected to see strong growth in the next few years. It will grow to $7.74 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%.

The projected growth is fueled by worsening hygiene conditions and changing climatic factors, increasing rates of chronic illnesses, a growing elderly population, a surge in cases of vulvovaginal candidiasis, and rising occurrences of cryptococcosis. Key trends expected in the market include the development of advanced drug delivery platforms, adoption of more cost-effective and modern diagnostic solutions, the integration of artificial intelligence in drug development processes, and AI-driven fungal infection diagnostics.

The growing prevalence of skin diseases is anticipated to drive the expansion of the topical antifungals market in the coming years. Skin diseases encompass conditions that affect the skin’s health, appearance, or function, such as irritation, inflammation, or infections. This increase in skin-related issues is largely attributed to greater exposure to environmental pollutants and ultraviolet (UV) radiation, both of which can harm the skin and trigger various disorders. Topical antifungals are used to treat these conditions by offering targeted action against fungal pathogens, minimizing systemic exposure, reducing adverse effects, and supporting faster healing of affected areas. For example, in April 2022, the American Journal of Managed Care, a US-based peer-reviewed journal, reported that 43% of 40,000 patients experienced at least one skin condition in the previous year. Additionally, in March 2023, the World Health Organization estimated that around 1.8 billion people worldwide are affected by skin conditions at any given time. As a result, the rising incidence of skin diseases is expected to propel the topical antifungals market.

Key players in the topical antifungals market are developing innovative treatments, including histone deacetylase (HDAC) inhibitors, to improve therapeutic outcomes, counter antifungal resistance, and enhance drug penetration in the nail bed for treating onychomycosis. HDAC inhibitors function by blocking histone deacetylase enzymes, which remove acetyl groups from histone proteins. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biotechnology firm, received FDA approval for its Investigational New Drug (IND) application to study VTR-297 as a treatment for onychomycosis, a prevalent fungal nail infection. VTR-297, a small-molecule HDAC inhibitor with antifungal properties, was originally derived from the bacterial species Streptomyces hygroscopicus and was first identified as an antifungal antibiotic.

In August 2022, Avista Capital Partners, a US-based private equity firm, acquired WellSpring Consumer Healthcare for an undisclosed sum. This acquisition was part of Avista's strategy to enhance its presence in the consumer healthcare market by utilizing WellSpring Consumer Healthcare's portfolio of over-the-counter (OTC) health and wellness products. WellSpring Consumer Healthcare specializes in the development of OTC medications and antifungal treatments.

Major players in the topical antifungals market are Pfizer Inc., Bayer AG, Novartis AG, GSK plc, Fresenius Kabi AG, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Galderma S.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, LUPIN LIMITED, Zydus Cadila, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd, Taro Pharmaceutical Industries Ltd., Natco Pharma Ltd, Femcorp Pharma, Glamris Dermacare.

North America was the largest region in the topical antifungals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in topical antifungals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Topical antifungals are medications intended for external application to treat fungal infections affecting the skin, nails, or mucous membranes. They work by either stopping fungal growth or eliminating the fungi altogether. These treatments are typically used for mild to moderate infections and help alleviate symptoms such as redness, itching, and swelling.

The key categories of topical antifungals include azoles, allylamines, echinocandins, and polyenes. Azoles act by blocking the synthesis of ergosterol, an essential component of fungal cell membranes. These drugs are available in various formulations such as creams, ointments, sprays, lotions, and powders. They are mainly used to address conditions like dermatophyte infections, candidiasis, tinea infections, and onychomycosis. Distribution channels include hospital pharmacies, retail drug stores, online pharmacies, and standard pharmacies, with end users spanning hospitals, clinics, pharmaceutical companies, and home healthcare providers.

The topical antifungals market research report is one of a series of new reports that provides topical antifungals market statistics, including the topical antifungals industry global market size, regional shares, competitors with the topical antifungals market share, detailed topical antifungals market segments, market trends, and opportunities, and any further data you may need to thrive in the topical antifungals industry. This topical antifungal market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The countries covered in the topical antifungals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The topical antifungals market consists of sales of clotrimazole, terbinafine, ketoconazole, econazole, and tolnaftate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.